Circulating biomarkers of tissue remodelling in pulmonary hypertension

被引:59
作者
Schumann, Christian [2 ]
Lepper, Philipp M. [3 ,4 ]
Frank, Hedwig [2 ]
Schneiderbauer, Roland [2 ]
Wibmer, Thomas [2 ]
Kropf, Cornelia [2 ]
Stoiber, Kathrin M. [2 ]
Ruediger, Stefan [2 ]
Kruska, Lothar [5 ]
Krahn, Thomas [1 ]
Kramer, Frank [1 ]
机构
[1] Bayer HealthCare, Global Biomarker Res, Wuppertal, Germany
[2] Univ Ulm, Clin Internal Med 2, Ulm, Germany
[3] Univ Bern, Bern, Switzerland
[4] Univ Bern, Inselspital, Univ Hosp, Dept Pneumol, CH-3010 Bern, Switzerland
[5] MVZ Dr Stein & Kollegen, Monchengladbach, Germany
关键词
Biomarkers; tissue remodelling; pulmonary hypertension; matrix metalloproteinase 2; tenascin C; tissue inhibitor of matrix metalloproteinase 4; BRAIN NATRIURETIC PEPTIDE; HEART-FAILURE; MATRIX METALLOPROTEINASES; SILDENAFIL; INHIBITORS; THERAPIES; SURVIVAL; CELLS;
D O I
10.3109/1354750X.2010.492431
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective: Besides persisting high pulmonary arterial pressure and increased pulmonary vascular resistance, remodelling of pulmonary tissues and subsequently the right heart are the key pathomechanisms of pulmonary hypertension (PH). Extracellular matrix maintenance in this context plays a central role. Methods: We tested the hypothesis that plasma concentration of matrix metalloproteinase (MMP)-2, tissue inhibitor of matrix metalloproteinases (TIMP)-4 and tenascin C (TNC) might be useful as biomarkers for assessing the severity of PH. Therefore, the concentrations of MMP-2, TIMP-4, TNC and N-terminal b-type natriuretic peptide (NT-proBNP) of 36 PH patients were compared with those of 44 age- and gender-matched healthy volunteers. Additionally, lung function, 6-min walk distance and right heart function were assessed. Results: In PH patients, significantly elevated plasma levels of MMP-2, TIMP-4, TNC and NT-proBNP were detected. In particular, TIMP-4 was significantly increased in patients with higher NYHA classification, and in patients with severe right ventricular hypertrophy. Conclusion: Monitoring of plasma TIMP-4 and to a lesser extent of MMP-2 and TNC levels in PH patients might help to assess the beneficial effects of PH pharmacotherapy on tissue remodelling.
引用
收藏
页码:523 / 532
页数:10
相关论文
共 38 条
[1]   Emerging therapies for pulmonary arterial hypertension [J].
Ali, Omar ;
Wharton, John ;
Simon, John ;
Gibbs, Russell ;
Howard, Luke ;
Wilkins, Martin Russell .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (06) :803-818
[2]   Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension [J].
Asosingh, Kewal ;
Aldred, Micheala A. ;
Vasanji, Arnit ;
Drazba, Judith ;
Sharp, Jacqueline ;
Farver, Carol ;
Comhair, Suzy A. A. ;
Xu, Weiling ;
Licina, Lauren ;
Huang, Lan ;
Anand-Apte, Bela ;
Yoder, Mervin C. ;
Tuder, Rubin M. ;
Erzurum, Serpil C. .
AMERICAN JOURNAL OF PATHOLOGY, 2008, 172 (03) :615-627
[3]   Management of pulmonary arterial hypertension with a focus on combination therapies [J].
Benza, Raymond L. ;
Park, Myung H. ;
Keogh, Anne ;
Girgis, Reda E. .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (05) :437-446
[4]   AN IMBALANCE BETWEEN THE EXCRETION OF THROMBOXANE AND PROSTACYCLIN METABOLITES IN PULMONARY-HYPERTENSION [J].
CHRISTMAN, BW ;
MCPHERSON, CD ;
NEWMAN, JH ;
KING, GA ;
BERNARD, GR ;
GROVES, BM ;
LOYD, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (02) :70-75
[5]   Diagnostic and prognostic usefulness of natriuretic peptides in emergency department patients with dyspnea [J].
Collins, SP ;
Ronan-Bentle, S ;
Storrow, AB .
ANNALS OF EMERGENCY MEDICINE, 2003, 41 (04) :532-545
[6]   Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease [J].
Cowan, KN ;
Jones, PL ;
Rabinovitch, M .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (01) :21-34
[7]   ATS statement: Guidelines for the six-minute walk test [J].
Crapo, RO ;
Casaburi, R ;
Coates, AL ;
Enright, PL ;
MacIntyre, NR ;
McKay, RT ;
Johnson, D ;
Wanger, JS ;
Zeballos, RJ ;
Bittner, V ;
Mottram, C .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (01) :111-117
[8]   SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY [J].
DALONZO, GE ;
BARST, RJ ;
AYRES, SM ;
BERGOFSKY, EH ;
BRUNDAGE, BH ;
DETRE, KM ;
FISHMAN, AP ;
GOLDRING, RM ;
GROVES, BM ;
KERNIS, JT ;
LEVY, PS ;
PIETRA, GG ;
REID, LM ;
REEVES, JT ;
RICH, S ;
VREIM, CE ;
WILLIAMS, GW ;
WU, M .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (05) :343-349
[9]  
Douglas Pamela S, 2007, J Am Coll Cardiol, V50, P187, DOI 10.1016/j.jacc.2007.05.003
[10]   Endothelin receptor antagonists in pulmonary arterial hypertension [J].
Dupuis, J. ;
Hoeper, M. M. .
EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (02) :407-415